Dr Mohammed Zayed
MBChB, MRCGP, MSc
Clinical Research Fellow
Mohammed graduated from Alexandria Medical School in Egypt in 2010 where he was awarded his MBChB degree with Honours. He then moved to the UK and completed his foundation training in 2012. He gained experience working in Ophthalmology and as a medical tutor in the Royal Hallamshire Hospital and the University of Sheffield between 2012 and 2014. He completed his GP training and obtained his MRCGP in Leeds in 2017 and was awarded the title of Visiting Lecturer at the University of Leeds.
He joined Swansea University Medical School in 2018 as an Academic GP and was awarded his MSc degree in Clinical Medicine with Distinction in 2021.
In 2020, Mohammed joined CTSU at the University of Oxford as a Clinical Research Fellow working on large randomised clinical trials including ORION-4 (a cardiovascular outcome trial of the cholesterol-lowering drug, inclisiran), LENS (a major streamlined study which is investigating the effect of the cholesterol-lowering drug, fenofibrate, on the progression of diabetic eye disease) and RECOVERY (an international clinical trial aims to identify treatments that may be beneficial for people hospitalised with suspected or confirmed COVID-19) . He is also a part-time GP and a GMC PLAB examiner.
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. Electronic address: firstname.lastname@example.org None. and RECOVERY Collaborative Group None., (2023), Lancet, 401, 1499 - 1507
Abstracts to the European Association for Diabetic Eye Complications (EAsDEC) 2023 Conference – Coimbra, Portugal, from 1st–3rd June 2023
(2023), European Journal of Ophthalmology, 33, S1 - S30
Empagliflozin in Patients with Chronic Kidney Disease.
The EMPA-KIDNEY Collaborative Group None. et al, (2023), N Engl J Med, 388, 117 - 127
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368
Care-pathways for patients presenting to emergency ambulance services with self-harm: national survey
Zayed MG. et al, (2020), Emergency Medicine Journal